Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Dewpoint Therapeutics, a US biotech developing condensate-modulating therapeutics, has announced the selection of a ...

BOSTON--(BUSINESS WIRE)--As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

BOSTON--(BUSINESS WIRE)--SOLA Biosciences, a pioneer in innovative chaperone technology, will present its encouraging preclinical proof-of-concept data for SOL-257, a targeted gene therapy for ...

Known as a keen sensor of mischief, TREM2 sets off microglial responses to Aβ, tau, and other markers of neuronal distress. A new study now adds pathological TDP-43 to that list. In a paper published ...

In amyotrophic lateral sclerosis and many cases of frontotemporal dementia, the RNA-binding protein TDP-43 abandons the nucleus and clumps up in cytoplasm, disrupting the normal workings of neurons ...

Niigata, Japan - Amyotrophic lateral sclerosis (ALS) is an intractable neurological disease. Aging is a risk factor for the accumulation of TDP-43 (transduction responsive region DNA-binding protein ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, researchers report 'seeding' this accumulation through fragments of the culprit ...

Frontotemporal dementia (FTD) is one of the most common causes of progressive dementia in working-age people. However, making a diagnosis and a prognosis is often challenging because the ...